Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 712,965 shares of the medical instruments supplier’s stock after purchasing an additional 1,007 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.31% of Becton, Dickinson and worth $139,705,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Guardian Life Insurance Co. of America increased its holdings in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after purchasing an additional 6 shares during the last quarter. Family Firm Inc. increased its holdings in shares of Becton, Dickinson and by 0.5% in the second quarter. Family Firm Inc. now owns 1,212 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 6 shares during the last quarter. Northwest Quadrant Wealth Management LLC increased its holdings in shares of Becton, Dickinson and by 0.4% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 1,686 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 6 shares during the last quarter. Wellington Shields & Co. LLC increased its holdings in shares of Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock valued at $496,000 after purchasing an additional 7 shares during the last quarter. Finally, Northstar Group Inc. increased its holdings in shares of Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock valued at $584,000 after purchasing an additional 9 shares during the last quarter. 86.01% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/sumitomo-mitsui-trust-holdings-inc-buys-1007-shares-of-becton-dickinson-and-company-bdx/1711944.html.

Becton, Dickinson and Company (NYSE BDX) traded down $1.21 on Friday, hitting $220.31. The stock had a trading volume of 718,967 shares, compared to its average volume of 1,325,275. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $225.23. The stock has a market capitalization of $50,410.00, a price-to-earnings ratio of 23.23, a P/E/G ratio of 1.73 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, topping the consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 22.51% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same period last year, the business posted $2.12 earnings per share. The company’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts expect that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

Several equities research analysts recently commented on BDX shares. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Barclays PLC reiterated an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $213.47.

In other news, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Gary M. Cohen sold 15,044 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $200.43, for a total value of $3,015,268.92. Following the transaction, the insider now owns 95,270 shares of the company’s stock, valued at $19,094,966.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,038 shares of company stock valued at $9,480,225. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.